Stryker Corporation (SYK) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics.
Total Cash From Operating Activities Chart for Stryker Corporation
Stryker Corporation (SYK) operating cash flow for FY2025 was USD 5.0B, a 18.9% change from FY2024. Stryker Corporation's operating cash flow grew from USD 21.5M in 1989 to USD 5.0B in 2025 (23360.5% over 36 years). Operating cash flow compound annual growth rate: 5-year CAGR of 9.0%, 10-year CAGR of 18.8%, 20-year CAGR of 9.2%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $129.43B
- Implied Share Price
- $337.43
- Enterprise Value
- $140.74B
- Revenue (TTM)
- $25.84B
- EBITDA
- $7.38B
- Profit Margin
- 14.43%
- Trailing P/E
- 34.97
- Forward P/E
- 22.37
- Price/Book (MRQ)
- 5.37
- Price/Sales (TTM)
- 5.01
- EV/EBITDA
- 20.14
- EV/Revenue
- 5.43
- Dividend Yield
- 1.03%
- Book Value
- $59.94
- Free Cash Flow (FY2025)
- $4.28B
- Free Cash Flow Yield
- 3.31%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.